Lilly Readies IDENTITY Trial To Treat Alzheimer’s
March 31, 2008
Boston (dbTechno) - Eli Lilly and Co. made the announcement on Monday that they are starting a Phase III clinical trial for treatment of Alzheimer’s disease.
Eli Lilly and Co. will be testing and studying LY450139 to see if it can slow or stop the progression of Alzheimer’s disease.
LY450139 is a gamma secretase inhibitor. Lilly has stated that the thought process is that if they can block gamma secretase, there will be less formation of amyloid beta.
Amyloid beta is a plaque which aids in the killing of brain cells, and the progression of Alzheimer’s.
The trial will be called IDENTITY, Interrupting Alzheimer’s Dementia by Evaluating Treatment of Amyloid Pathology.
Comments
2 Responses to “Lilly Readies IDENTITY Trial To Treat Alzheimer’s”
All comments are moderated.
If your comment is approved, it will be posted within 24 hours
Breaking News
Sandra Bullock Not Attending London Movie PremierBoston (DbTechNo) - It is being reported that actress Sandra Bullock will not be attending the London premiere of The Blind...
Environmental Protection Agency Reviewing Fle and Tick Product LabellingThe Environmental Protection Agency (EPA) will be taking a closer look at flea and tick products for dogs and cats after...
American Idol Wannabes Take to the StageAmerican Idol featured performances by the top 12 contestants last night, all of whom sang a song from the Rolling Stones. As...
How will this relate to someone with Lewy Body Dementia who has symptoms of Alzheimers? Or is LBD a stand alone dementia hence the lewy bodies that appear in the brain….please clarify the difference. Thank you.
Has to have had some success to get to Phase III. Since I’m a young senior citizen I hope that LY450139 works with minimal side effects. I’ve witnessed with my own family and as a former psychiatric nurse how well the dementia drugs, already approved have benefited those afflicted with the various dementias.